Aim
To assess whether the
introduction of a prison‐based opioid substitution therapy (OST) policy was
associated with a reduction in drug‐related deaths (DRD) within 14 days after prison release.
Design
Linkage of Scotland's
prisoner database with death registrations to compare periods before
(1996–2002) and after (2003–07) prison‐based OST was introduced.
Setting
All Scottish prisons.
Participants
People released from
prison between 1 January 1996 and 8 October 2007 following an imprisonment of
at least 14 days and at least 14 weeks after the preceding qualifying release.
Measurements
Risk of DRD in the
12 weeks following release; percentage of these DRDs which occurred during the
first 14 days.
Findings
Before prison‐based OST (1996–2002), 305 DRDs
occurred in the 12 weeks after 80 200 qualifying releases, 3.8 per 1000
releases [95% confidence interval (CI) = 3.4–4.2]; of these, 175 (57%) occurred
in the first 14 days. After the introduction of prison‐based OST (2003–07), 154 DRDs
occurred in the 12 weeks after 70 317 qualifying releases, a significantly
reduced rate of 2.2 per 1000 releases (95% CI = 1.8–2.5). However, there was no
change in the proportion which occurred in the first 14 days, either for all
DRDs (87: 56%) or for opioid‐related DRDs.
Conclusions
Following the
introduction of a prison‐based opioid substitution therapy (OST) policy in Scotland,
the rate of drug‐related deaths in the 12 weeks following release fell by
two‐fifths. However,
the proportion of deaths that occurred in the first 14 days did not change
appreciably, suggesting that in‐prison OST does not reduce early deaths after release.
Full article at: http://goo.gl/Zb7RcW
By: Sheila M. Bird, 1 Colin M. Fischbacher, 2 Lesley Graham, 2 and Andrew Fraser 3
1MRC Biostatistics Unit, Cambridge, UK
2NHS National Services Scotland, Edinburgh,
UK
3NHS Health Scotland, Edinburgh, UK
Corresponding
author.
*Correspondence to: Sheila M. Bird,
MRC Biostatistics Unit, Cambridge CB2 0SR, UK. E‐mail: ku.ca.mac.usb-crm@drib.aliehs
More at: https://twitter.com/hiv insight
No comments:
Post a Comment